Bosutinib is a type of leukemia drug used to treat chronic myelogenous leukemia (CML). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of the BCR-ABL protein, which is responsible for the growth of CML cells. Bosutinib is approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase. It is also approved for the treatment of adult patients with CML in chronic phase who are resistant or intolerant to prior therapy. Bosutinib is marketed by Pfizer under the brand name Bosulif. Other companies that produce and market Bosutinib include Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
